Literature DB >> 19196915

Elevated levels of activin A in clinical and experimental pulmonary hypertension.

Arne Yndestad1, Karl-Otto Larsen, Erik Oie, Thor Ueland, Camilla Smith, Bente Halvorsen, Ivar Sjaastad, Ole Henning Skjønsberg, Turid M Pedersen, Ole-Gunnar Anfinsen, Jan Kristian Damås, Geir Christensen, Pål Aukrust, Arne K Andreassen.   

Abstract

Activin A, a member of the transforming growth factor (TGF)-beta superfamily, is involved in regulation of tissue remodeling and inflammation. Herein, we wanted to explore a role for activin A in pulmonary hypertension (PH). Circulating levels of activin A and its binding protein follistatin were measured in patients with PH (n = 47) and control subjects (n = 14). To investigate synthesis and localization of pulmonary activin A, we utilized an experimental model of hypoxia-induced PH. In mouse lungs, we also explored signaling pathways that can be activated by activin A, such as phosphorylation of Smads, which are mediators of TGF-beta signaling. Possible pathophysiological mechanisms initiated by activin A were explored by exposing pulmonary arterial smooth muscle cells in culture to this cytokine. Elevated levels of activin A and follistatin were found in patients with PH, and activin A levels were significantly related to mortality. Immunohistochemistry of lung autopsies from PH patients and lungs with experimental PH localized activin A primarily to alveolar macrophages and bronchial epithelial cells. Mice with PH exhibited increased pulmonary levels of mRNA for activin A and follistatin in the lungs, and also elevated pulmonary levels of phosphorylated Smad2. Finally, we found that activin A increased proliferation and induced gene expression of endothelin-1 and plasminogen activator inhibitor-1 in pulmonary artery smooth muscle cells, mediators that could contribute to vascular remodeling. Our findings in both clinical and experimental studies suggest a role for activin A in the development of various types of PH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19196915     DOI: 10.1152/japplphysiol.90719.2008

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  13 in total

1.  Activin A Predicts Left Ventricular Remodeling and Mortality in Patients with ST-Elevation Myocardial Infarction.

Authors:  Jeng-Feng Lin; Shun-Yi Hsu; Ming-Sheng Teng; Semon Wu; Chien-An Hsieh; Shih-Jung Jang; Chih-Jen Liu; Hsuan-Li Huang; Yu-Lin Ko
Journal:  Acta Cardiol Sin       Date:  2016-07       Impact factor: 2.672

2.  Noggin inhibits hypoxia-induced proliferation by targeting store-operated calcium entry and transient receptor potential cation channels.

Authors:  Kai Yang; Wenju Lu; Jing Jia; Jie Zhang; Mingming Zhao; Sabrina Wang; Haiyang Jiang; Lei Xu; Jian Wang
Journal:  Am J Physiol Cell Physiol       Date:  2015-03-04       Impact factor: 4.249

3.  Activin A levels are associated with abnormal glucose regulation in patients with myocardial infarction: potential counteracting effects of activin A on inflammation.

Authors:  Geir Ø Andersen; Thor Ueland; Eva C Knudsen; Hanne Scholz; Arne Yndestad; Afaf Sahraoui; Camilla Smith; Tove Lekva; Kari Otterdal; Bente Halvorsen; Ingebjørg Seljeflot; Pål Aukrust
Journal:  Diabetes       Date:  2011-04-04       Impact factor: 9.461

4.  Vitamin D supplementation lowers thrombospondin-1 levels and blood pressure in healthy adults.

Authors:  Anjalee T Amarasekera; Bahador Assadi-Khansari; Saifei Liu; Marilyn Black; Greer Dymmott; Natasha M Rogers; Aaron L Sverdlov; John D Horowitz; Doan T M Ngo
Journal:  PLoS One       Date:  2017-05-10       Impact factor: 3.240

5.  Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk.

Authors:  Helen R Warren; Evangelos Evangelou; Claudia P Cabrera; He Gao; Meixia Ren; Borbala Mifsud; Ioanna Ntalla; Praveen Surendran; Chunyu Liu; James P Cook; Aldi T Kraja; Fotios Drenos; Marie Loh; Niek Verweij; Jonathan Marten; Ibrahim Karaman; Marcelo P Segura Lepe; Paul F O'Reilly; Joanne Knight; Harold Snieder; Norihiro Kato; Jiang He; E Shyong Tai; M Abdullah Said; David Porteous; Maris Alver; Neil Poulter; Martin Farrall; Ron T Gansevoort; Sandosh Padmanabhan; Reedik Mägi; Alice Stanton; John Connell; Stephan J L Bakker; Andres Metspalu; Denis C Shields; Simon Thom; Morris Brown; Peter Sever; Tõnu Esko; Caroline Hayward; Pim van der Harst; Danish Saleheen; Rajiv Chowdhury; John C Chambers; Daniel I Chasman; Aravinda Chakravarti; Christopher Newton-Cheh; Cecilia M Lindgren; Daniel Levy; Jaspal S Kooner; Bernard Keavney; Maciej Tomaszewski; Nilesh J Samani; Joanna M M Howson; Martin D Tobin; Patricia B Munroe; Georg B Ehret; Louise V Wain
Journal:  Nat Genet       Date:  2017-01-30       Impact factor: 38.330

Review 6.  Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus.

Authors:  Benjamin J Dunmore; Rowena J Jones; Mark R Toshner; Paul D Upton; Nicholas W Morrell
Journal:  Cardiovasc Res       Date:  2021-09-28       Impact factor: 10.787

Review 7.  Receptor binding competition: A paradigm for regulating TGF-β family action.

Authors:  Erik Martinez-Hackert; Anders Sundan; Toril Holien
Journal:  Cytokine Growth Factor Rev       Date:  2020-10-06       Impact factor: 7.638

8.  The α and Δ isoforms of CREB1 are required to maintain normal pulmonary vascular resistance.

Authors:  Lili Li; Katherine Howell; Michelle Sands; Mark Banahan; Stephen Frohlich; Simon C Rowan; Roisín Neary; Donal Ryan; Paul McLoughlin
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

9.  Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.

Authors:  Marc Iglarz; Kyle Landskroner; Yasmina Bauer; Magali Vercauteren; Markus Rey; Berengère Renault; Rolf Studer; Enrico Vezzali; Diego Freti; Hakim Hadana; Manuela Schläpfer; Christophe Cattaneo; Céline Bortolamiol; Edgar Weber; Brian R Whitby; Stéphane Delahaye; Daniel Wanner; Pauline Steiner; Oliver Nayler; Patrick Hess; Martine Clozel
Journal:  J Cardiovasc Pharmacol       Date:  2015-11       Impact factor: 3.105

10.  Inhibitory Antibodies against Activin A and TGF-β Reduce Self-Supported, but Not Soluble Factors-Induced Growth of Human Pulmonary Arterial Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension.

Authors:  Tatiana V Kudryashova; Yuanjun Shen; Andressa Pena; Emily Cronin; Evelyn Okorie; Dmitry A Goncharov; Elena A Goncharova
Journal:  Int J Mol Sci       Date:  2018-09-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.